Keywords: GlaxoSmithKline, Takeda, Avandia, Actos, Cardiovascular risk

New study finds little difference in cardiac risk for GlaxoSmithKline’s Avandia and Takeda’s Actos

Article | 25 August 2010

Print This

In contrast to previous reports, the risks of the composite endpoint of heart attack, heart failure, both, or death were ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in